-
1.发明申请公开(公告)号：US20120142743A1
公开(公告)日：2012-06-07
申请号：US13369934
申请日：2012-02-09
申请人： Aleksandar DANILOVSKI , Maja DEVCIC , Marina MARINKOVIC , Ernest MESTROVIC , Tina MUNDORFER , Iva TUNJIC
发明人： Aleksandar DANILOVSKI , Maja DEVCIC , Marina MARINKOVIC , Ernest MESTROVIC , Tina MUNDORFER , Iva TUNJIC
CPC分类号： C07D213/75
摘要： New polymorphic forms of flupirtine maleate are described.
摘要翻译： 描述了氟替菲汀马来酸盐的新的多晶型物。
-
公开(公告)号：US20070225325A1
公开(公告)日：2007-09-27
申请号：US10587537
申请日：2005-01-19
申请人： Ernest Mestrovic , Michaela Horvat , Maja Devcic , Amir Avdagic , Dominik Cincic , Marina Marinkovic
发明人： Ernest Mestrovic , Michaela Horvat , Maja Devcic , Amir Avdagic , Dominik Cincic , Marina Marinkovic
IPC分类号： C07D215/00
CPC分类号： C07D215/18
摘要： Differing forms of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid and methods for synthesizing same.
摘要翻译： - （（（（1（R） - （3-（2-（7-氯-2-喹啉基）乙烯基） - 苯基）-3-（2-（1-羟基-1-甲基乙基）苯基） 丙基）硫基）甲基）环丙烷乙酸及其合成方法。
-
3.发明授权Amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, process for preparing the same, and uses thereof 失效无定形9-脱氧-9a-氮杂-9a-甲基-9a-高红霉素A，其制备方法及其用途公开(公告)号：US06936591B2
公开(公告)日：2005-08-30
申请号：US10624911
申请日：2003-07-21
申请人： Miljenko Dumić , Mladen Vinković , Marina Oresic , Ernest Mestrovic , Aleksandar Danilovski , Alojz Dumbovic , Knezevic Zdravka , Gorjana Lazarevski , Darko Filic , Dominik Cincic , Katica Lazaric , Dejan-Kresimir Bucar
发明人： Miljenko Dumić , Mladen Vinković , Marina Oresic , Ernest Mestrovic , Aleksandar Danilovski , Alojz Dumbovic , Knezevic Zdravka , Gorjana Lazarevski , Darko Filic , Dominik Cincic , Katica Lazaric , Dejan-Kresimir Bucar
CPC分类号： C07H17/08
摘要： Substantially pure amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. In addition, this disclosure is directed to a process for the preparation thereof from crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A via orthorhombic isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, of the general formula I: wherein S represents a water-miscible or water-immiscible organic solvent, characterized by the orthorhombic space group P212121, with average unit cell parameters a=8.2 to 9.7 Å, b=11.5 to 13.5 Å, c=44.5 to 47.0 Å, α=β=γ=90°, wherein a, b and c represent the crystal axes lengths and α, β and γ represent the angles between the crystal axes. In addition, pharmaceutical compositions containing the substantially pure amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A are disclosed, as well as a method for the treatment of bacterial and protozoal infections, and inflammation related diseases in humans and animals by administration of a pharmaceutical composition containing same.
摘要翻译： 基本上纯的无定形9-脱氧-9a-氮杂-9a-甲基-9a-高红霉素A.此外，本发明涉及一种由9-脱氧-9a-氮杂-9a-甲基-9a- 通过通式I的9-脱氧-9a-氮杂-9a-甲基-9a-高红霉素A的正交同构异构体假多晶型物的同型红霉素A：其中S表示水混溶性或水不混溶性有机溶剂，其特征在于正交空间群 其中平均单元电池参数a = 8.2至9.7，b = 11.5至13.5，c = 44.5 至47.0A，α=β=γ= 90°，其中a，b和c表示晶轴长度，α，β和γ表示晶轴之间的角度。 此外，公开了含有基本上纯的无定形9-脱氧-9a-氮杂-9a-甲基-9a-高红霉素A的药物组合物，以及用于治疗细菌和原生动物感染以及与人类发生炎症有关的疾病的方法 动物通过施用含有它们的药物组合物。
-
4.发明授权Isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A 有权9-脱氧-9a-氮杂-9a-甲基-9a-高红霉素A的异构体假多晶型物公开(公告)号：US07569549B2
公开(公告)日：2009-08-04
申请号：US10390573
申请日：2003-03-17
申请人： Miljenko Dumic , Mladen Vinkovic , Marina Oresic , Ernest Mestrovic , Aleksandar Danilovski , Alojz Dumbovic , Zdravka Knezevic , Gorjana Lazarevski , Dominik Cincic , Darko Filic , Katica Lazaric , Dejan Kresimir Bucar
发明人： Miljenko Dumic , Mladen Vinkovic , Marina Oresic , Ernest Mestrovic , Aleksandar Danilovski , Alojz Dumbovic , Zdravka Knezevic , Gorjana Lazarevski , Dominik Cincic , Darko Filic , Katica Lazaric , Dejan Kresimir Bucar
摘要： Substantially pure isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A having the Formula I: wherein S is an organic solvent which is at least partially miscible with water, x is 1, 1.25, 1.5 or 2, y is 0, 0.5, or 1, the pseudopolymorph being characterized by the monoclinic space group P21 and average unit cell parameters comprising: crystal axis lengths of a=15.5-17.0 Å, b=15.5-17.0 Å, and c=17.5-19.5 Å, and angles between the crystal axes of α=γ=90° and β=106°-112°. In addition, this disclosure is directed to processes for the preparation of the substantially pure isostructural pseudopolymorphs of Formula I; to pharmaceutical compositions containing substantially pure isostructural pseudopolymorphs of Formula I; and to a method for the treatment of bacterial and protozoan infections, and inflammation-related diseases by administration of a pharmaceutical composition containing the substantially pure isostructural pseudopolymorphs of Formula I.
摘要翻译： 具有式I的9-脱氧-9a-氮杂-9a-甲基-9a-高红霉素A的基本上纯的同态结构假多晶型物：其中S是与水至少部分混溶的有机溶剂，x为1,1.25,1.5或2 ，y为0,0.5或1，所述假多晶型物的特征在于单斜晶系空间群P21和平均晶胞参数，其包括：晶轴长度a =15.5-17.0，b =15.5-17.0，c = 17.5- α=γ= 90°和β= 106°-112°的晶轴之间的角度。 此外，本公开涉及制备式I的基本上纯的同态结构假多晶型物的方法; 包含基本上纯的式I的同态假多晶型物的药物组合物; 以及用于治疗细菌和原生动物感染以及炎症相关疾病的方法，其通过施用含有基本上纯的式I的同型结构假多晶型物的药物组合物。
-
公开(公告)号：US20090149427A1
公开(公告)日：2009-06-11
申请号：US12088545
申请日：2006-09-04
申请人： Kreso Mihaljevic , Blazenko Bajic , Drazen Cavuzic , Ernest Mestrovic , Miroslav Zegarac , Nada Kosutic Hulita
发明人： Kreso Mihaljevic , Blazenko Bajic , Drazen Cavuzic , Ernest Mestrovic , Miroslav Zegarac , Nada Kosutic Hulita
IPC分类号： A61K31/675 , C07F9/28 , A61P35/00
CPC分类号： C07F9/58
摘要： The present invention is concerned with new hydrated forms of risedronate salts, processes of preparing the new hydrated forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same. In particular, the present invention provides tri-sodium risedronate dihydrate.
摘要翻译： 本发明涉及利塞膦酸盐的新的水合形式，制备新的水合形式的方法，含有它们的药物组合物，其治疗用途和使用它们的治疗方法。 特别地，本发明提供了利塞膦酸三钠二水合物。
-
6.发明申请PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL 审中-公开二苯醚及其中间体化合物的制备方法，作为二苯醚的水合物公开(公告)号：US20090137811A1
公开(公告)日：2009-05-28
申请号：US11997102
申请日：2006-07-14
申请人： Andrzej Manikowski , Barbara Ziobro , Andrzej Zaba , Mieczyslaw Makosza , Juraj Jerkovic , Ivica Grebenar , Ernest Mestrovic , Zrinka Mastelic Samardzic , Lidija Lerman , Katarzyna Kaczorowska
发明人： Andrzej Manikowski , Barbara Ziobro , Andrzej Zaba , Mieczyslaw Makosza , Juraj Jerkovic , Ivica Grebenar , Ernest Mestrovic , Zrinka Mastelic Samardzic , Lidija Lerman , Katarzyna Kaczorowska
IPC分类号： C07D211/02 , C07D213/02 , C07D211/00
CPC分类号： C07D211/32
摘要： The present invention relates to a new process for the preparation of intermediate compounds useful in the manufacture of donepezil, or a pharmaceutically-acceptable salt thereof, and also relates to processes for preparing donepezil and to the novel intermediates per se. In addition the invention relates to various hydrated forms of donepezil.
摘要翻译： 本发明涉及制备可用于制备多奈哌齐的中间体化合物或其药学上可接受的盐的新方法，并且涉及本发明的制备多奈哌齐和新中间体的方法。 此外，本发明涉及多奈哌齐的各种水合形式。
-
公开(公告)号：US20080145425A1
公开(公告)日：2008-06-19
申请号：US11611305
申请日：2006-12-15
IPC分类号： A61K31/437 , A61K9/32 , A61P25/00
CPC分类号： A61K31/437 , A61K9/2018 , A61K9/2826 , A61K9/2866 , A61K9/4808
摘要： A pharmaceutical composition comprising a Zolpidem hemitartrate starting material comprised of form A, the composition containing less than about 8% by weight of water. The starting material typically comprises less than about 0.1% by weight of forms of Zolpidem other than Form A.
摘要翻译： 一种药物组合物，其包含由形式A组成的起始酒石酸根霉素，所述组合物含有小于约8重量％的水。 起始物质通常包含小于约0.1重量％的形式A以外的唑吡旦的形式。
-
8.发明申请Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate 有权马来酸氟吡汀的药学上可接受的盐和多晶型物公开(公告)号：US20110184030A1
公开(公告)日：2011-07-28
申请号：US12309260
申请日：2007-07-13
申请人： Aleksandar Danilovski , Maja Devcic , Marina Marinkovic , Ernest Mestrovic , Tina Mundorfer , Iva Tunjic
发明人： Aleksandar Danilovski , Maja Devcic , Marina Marinkovic , Ernest Mestrovic , Tina Mundorfer , Iva Tunjic
IPC分类号： A61K31/44 , C07D213/75 , A61P25/04 , A61P25/16 , A61P21/02
CPC分类号： C07D213/75
摘要： The present invention is concerned with new polymorphic forms of flupirtine maleate, processes for preparing the new polymorphic forms, pharmaceutical compositions containing them, therapeutic uses thereof and methods of treatment employing them.
摘要翻译： 本发明涉及马来酸氟吡汀的新型多晶型物，新型多晶型物的制备方法，含有它们的药物组合物，其治疗用途和使用它们的治疗方法。
-
公开(公告)号：US20090137613A1
公开(公告)日：2009-05-28
申请号：US12293239
申请日：2007-03-06
IPC分类号： A61K31/522
CPC分类号： C07D473/32
摘要： The present invention is concerned with new pharmaceutically acceptable salts of valacyclovir, polymorphic forms, processes for preparing the new pharmaceutically acceptable salts and new polymorphic forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same.
摘要翻译： 本发明涉及新的可待因的伐昔洛韦盐，多晶型物，制备新的药学上可接受的盐和新的多晶型物的方法，含有它们的药物组合物，其治疗用途和使用该盐的治疗方法。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.014 秒)
